Emerging research suggest this peptide, a dual activator targeting both GLP-1 and another hormone, appears to offer a significant step forward for obesity loss . Early clinical investigations have indicated impressive reductions in visceral fat , conceivably surpassing current weight-loss therapies . Despite this, further evaluation is required to